IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of cash flow for the year ended December 31

(in CHF 1 000)

 

 

Notes

 

2020

 

2019

Cash flows from operating activities

 

 

 

 

 

 

Proceeds from sales of securities

 

4

 

1 008 571

 

754 160

Purchase of securities

 

4

 

(699 354)

 

(493 508)

Dividend receipts

 

 

 

243

 

1 156

Interest receipts

 

 

 

7

 

41

Payments for services

 

 

 

(46 973)

 

(46 789)

Income taxes paid

 

 

 

(45)

 

(39)

Total cash flows from operating activities

 

 

 

262 449

 

215 021

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

Dividend

 

 

 

(188 360)

 

(168 970)

Proceeds from sales of treasury shares

 

7

 

20

 

Purchase of treasury shares

 

7

 

(8 260)

 

Repayment of bank loans

 

5

 

(87 000)

 

(35 000)

Interest payments

 

 

 

(883)

 

(1 243)

Total cash flows from financing activities

 

 

 

(284 483)

 

(205 213)

 

 

 

 

 

 

 

Foreign exchange difference

 

 

 

(1 857)

 

(1 173)

Change in cash and cash equivalents

 

 

 

(23 891)

 

8 635

 

 

 

 

 

 

 

Cash and cash equivalents at the beginning of the year

 

 

 

30 707

 

22 072

 

 

 

 

 

 

 

Cash and cash equivalents at the end of the year

 

 

 

6 816

 

30 707

The notes are an integral part of the consolidated financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer